Chad Klug, NP
Acute Care · Baton Rouge, LANPI 1780835215
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,172 of the $8,333 with a category attached, or 86.1%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Amgen$789
- Novartis$702
- Bayer$482
- Medtronic$474
- Johnson & Johnson$470
- plus $4K from 27 others
What the payments were for
- Consulting fees$2002%
- Travel & lodging$85510%
- Food & beverage$7,17286%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 12 | $1,427 |
| Amgen | 43 | $789 |
| Novartis | 53 | $702 |
| Bayer | 15 | $482 |
| Medtronic | 7 | $474 |
| Johnson & Johnson | 30 | $470 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $449 |
| Merck | 22 | $396 |
| AstraZeneca(2 entities) | 15 | $388 |
| Pfizer | 20 | $358 |
| Esperion Therapeutics, Inc. | 22 | $350 |
| Kestra Medical Technology Services, Inc. | 15 | $279 |
| E.r. Squibb & Sons, L.L.C. | 12 | $195 |
| Sanofi-aventis U.S. LLC | 9 | $180 |
| Cvrx, Inc. | 4 | $154 |
| Boehringer Ingelheim | 6 | $154 |
| Regeneron Healthcare Solutions, Inc. | 7 | $149 |
| Janssen Scientific Affairs, LLC | 3 | $146 |
| Amarin Pharma, Inc. | 7 | $130 |
| Actelion Pharmaceuticals US, Inc. | 2 | $123 |
| Novo Nordisk | 5 | $104 |
| Vifor Pharma, Inc. | 4 | $70 |
| Abbott | 2 | $54 |
| Chiesi USA, Inc. | 3 | $50 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| United Therapeutics Corporation | 1 | $27 |
| BTG International Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$368
- Adempas$200
- FARXIGA$122
- Repatha$119
- XARELTO$109
How this compares
$8,333 in reported general payments places this provider in the 95th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,025 | $996,116 |
| EntrestoSacubitril/Valsartan | 393 | $452,600 |
| XareltoRivaroxaban | 419 | $432,580 |
| Repatha SureclickEvolocumab | 183 | $174,106 |
| JardianceEmpagliflozin | 125 | $153,049 |
| FarxigaDapagliflozin Propanediol | 65 | $73,815 |
| NexlizetBempedoic Acid/Ezetimibe | 37 | $38,925 |
| NexletolBempedoic Acid | 40 | $30,260 |
| BrilintaTicagrelor | 33 | $22,793 |
| Praluent PenAlirocumab | 14 | $20,006 |
| Metoprolol Succinate | 1,492 | $18,127 |
| Dofetilide | 61 | $16,189 |
| Atorvastatin Calcium | 1,161 | $13,553 |
| VascepaIcosapent Ethyl | 25 | $11,492 |
| Rosuvastatin Calcium | 493 | $6,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $358 | $996,1161,025 claims |
| NovartisEntresto | $702 | $452,600393 claims |
| Johnson & JohnsonXarelto | $470 | $432,580419 claims |
| Boehringer IngelheimJardiance | $154 | $153,049125 claims |
| AstraZenecaFarxiga, Brilinta | $388 | $96,60898 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $350 | $69,18577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 acute care providers in Louisiana.
Other acute care in Baton Rouge
- Emily BurkeBaton Rouge$6K
- Mallory PriceBaton Rouge$3K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Charles JarreauNew Orleans$40K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Jeremy TerroLafayette$11K
- Mary HireShreveport$11K
- Jacquelyn CosterHouma$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.